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Introduction {#ehf212209-sec-0004}
============

Heart failure (HF) is a complex clinical syndrome and carries a poor prognosis, and this syndrome is progressive and characterized by worsening quality of life. Importantly, the prevalence of HF increases dramatically with age, and therefore, elderly people represent over 80% of all HF patients.[1](#ehf212209-bib-0001){ref-type="ref"} The majority of elderly HF patients presents with co‐morbidities. Co‐morbidities are generally considered to have strong impact on physical function, quality of life, and survival of patients with HF in late life.

Muscle wasting is not only a problem in the elderly but also a co‐morbidity of chronic diseases such as HF.[2](#ehf212209-bib-0002){ref-type="ref"} Our group has recently demonstrated that muscle wasting, as defined using the criteria for sarcopenia, is present in nearly 20% of ambulatory HF patients and that affected HF patients have an impaired physical function.[3](#ehf212209-bib-0003){ref-type="ref"}, [4](#ehf212209-bib-0004){ref-type="ref"} In addition, cachexia, associated with various pathophysiological mechanisms including neuroendocrine abnormalities, inflammatory system activation, increased lipolysis, and muscle wasting, affects about 10‐15% of patients with HF, and its presence is also an independent predictor of poor overall prognosis.[5](#ehf212209-bib-0005){ref-type="ref"}, [6](#ehf212209-bib-0006){ref-type="ref"} Overall, a wasting continuum from sarcopenia to cachexia has been proposed to occur in patients with advanced HF.[7](#ehf212209-bib-0007){ref-type="ref"}, [8](#ehf212209-bib-0008){ref-type="ref"}

Currently, it is acknowledged that the term malnutrition suggests a nutritional problem or failure, according to the combination of loss of food intake with age‐related changes and other HF‐related co‐morbidities. Anorexia, defined as the loss of desire to eat, is a multifactorial process, despite caloric deprivation is frequently seen in HF patients.[9](#ehf212209-bib-0009){ref-type="ref"}, [10](#ehf212209-bib-0010){ref-type="ref"} Anorexia is also reported as an independent and strong predictor of morbidity and mortality among patients in various clinical settings.[11](#ehf212209-bib-0011){ref-type="ref"} In oncology patients, the anorexia--cachexia syndrome is diagnosed as weight loss accompanied by anorexia, associated with impaired functional capacity and worse outcomes.[12](#ehf212209-bib-0012){ref-type="ref"} Despite the growing importance of anorexia, cachexia, and functional capacity for quality of life, there is still a lack of information explaining whether and how they relate to each other in patients with HF.[13](#ehf212209-bib-0013){ref-type="ref"} However, the reasons for anorexia are multifactorial; drug therapy, hepatic or gastrointestinal congestion and gastrointestinal dysfunction, and metabolic disturbance could affect appetite. Therefore, the determinants of anorexia and influence of anorexia on functional capacity and outcome are of outstanding interests in patients with HF.

Using data from the Studies Investigating Co‐morbidities Aggravating HF (SICA‐HF), a prospective, observational study into the co‐morbidities of chronic HF,[14](#ehf212209-bib-0014){ref-type="ref"} we aimed to investigate predictors of anorexia and to assess the association with functional capacity and outcomes in ambulatory patients with HF.

Methods {#ehf212209-sec-0005}
=======

Study design and patients {#ehf212209-sec-0006}
-------------------------

Between February 2010 and March 2014, we enrolled clinically stable 328 ambulatory patients into SICA‐HF at Charité‐Universitätsmedizin Berlin, Campus Virchow‐Klinikum, Berlin, Germany, 166 of whom answered a 6‐point Likert scale to assess the presence of anorexia. The study was funded by the European Commission\'s 7th Framework programme (FP7/2007--2013) under grant agreement number 241558 and fulfils all principles of the Declaration of Helsinki. SICA‐HF is registered under the [ClinicalTrials.gov](http://ClinicalTrials.gov) unique identifier: NCT01872299. Clinically stable ambulatory patients with chronic HF were eligible if they satisfied the following criteria: age \> 18 years old and clinical signs and symptoms of chronic HF with (i) a left ventricular ejection fraction (LVEF) ≤ 40%, (ii) a left atrial dimension *\>* 2.5 cm/m height, (iii) a left atrial dimension *\>* 4.0 cm, or (iv) N terminal pro brain natriuretic peptide *\>* 400 pg/mL or BNP *\>* 150 pg/mL. Patients with previous heart transplantation or a history of unstable angina, myocardial infarction, stroke, cardiovascular revascularization, or open abdominal surgery within 6 weeks prior to enrolment were excluded.[14](#ehf212209-bib-0014){ref-type="ref"} In the SICA‐HF study protocol, patients were divided according to LVEF into HF with reduced ejection fraction with LVEF ≤ 40% and HF with LVEF \> 40% and a left atrial dimension \> 4.0 cm (HF with preserved ejection fraction).[3](#ehf212209-bib-0003){ref-type="ref"}, [14](#ehf212209-bib-0014){ref-type="ref"} In patients with HF, medications consisted of angiotensin‐converting enzyme inhibitors, angiotensin receptor blockers, beta‐blockers, digoxin, diuretics including loop diuretics and thiazides, aspirin, statins, and amiodarone in varying combinations.

Evaluation of anorexia {#ehf212209-sec-0007}
----------------------

A single‐item measure was used to assess the presence of anorexia in all participants.[15](#ehf212209-bib-0015){ref-type="ref"}, [16](#ehf212209-bib-0016){ref-type="ref"} Subjects were asked to answer the question 'Do you have appetite loss?' (rated as 6‐point Likert scale 0 = not at all, 1 = very rarely, 2 = rarely, 3 = occasionally, 4 = frequently, and 5 = very frequently with higher number indicating increased frequency of anorexia). A cut‐off value ≥ 1 on the anorexia scale was used to define anorexia, because the response option 'very rarely' indicates that patients experience their appetite to be different from normal ('not at all'), which was described by Blauwhoff‐Buskermolen.[16](#ehf212209-bib-0016){ref-type="ref"}

Nutritional assessment {#ehf212209-sec-0008}
----------------------

The Nutritional Risk Index (NRI), an easily calculated measure that incorporates albumin and body size, predicts mortality in ambulatory and hospitalized HF patients.[17](#ehf212209-bib-0017){ref-type="ref"}, [18](#ehf212209-bib-0018){ref-type="ref"}, [19](#ehf212209-bib-0019){ref-type="ref"} NRI was calculated as NRI = (1.519 × serum albumin, g/dL) + {41.7 × present weight (kg)/usual weight (kg)} as previously described. The ideal body weight (IBW) was used as usual weight, and calculated with the Devine formula for men \[IBW (kg) = 50 kg + 2.3 kg for each inch of 110 height \>5 ft\] and the Robinson formula for women \[IBW (kg) = 48.67 kg + 1.65 kg for each inch of height \>5 ft\].[20](#ehf212209-bib-0020){ref-type="ref"} As in other previous studies, in patients with present weight greater than IBW, we set this ratio =1.[21](#ehf212209-bib-0021){ref-type="ref"}

Body composition and assessment of muscle wasting (sarcopenia) {#ehf212209-sec-0009}
--------------------------------------------------------------

Dual‐energy X‐ray absorptiometry was used to evaluate body composition such as total and appendicular lean and fat mass. Appendicular lean mass was defined as the lean mass of both arms and legs combined.[22](#ehf212209-bib-0022){ref-type="ref"}, [23](#ehf212209-bib-0023){ref-type="ref"} A scanner model 'Lunar Prodigy' and 'Lunar [en core]{.smallcaps} 2002' software was used to analyse the data (GE Medical Systems, Madison, WI, USA). Muscle wasting was defined according to previously published criteria for sarcopenia,[24](#ehf212209-bib-0024){ref-type="ref"} that is appendicular skeletal muscle mass 2 standard deviations below the mean of a healthy young reference group aged 18--40 years old. The appendicular muscle mass index was calculated as the lean mass of both arms and legs combined divided by the height in metre squared.[22](#ehf212209-bib-0022){ref-type="ref"}

Evaluation of cachexia {#ehf212209-sec-0010}
----------------------

Body weight was measured with light clothes without shoes. Body weight change history up to 24 months prior to enrolment was documented based on medical reports or patients\' personal statements. Cachexia was defined according to the current consensus‐based diagnostic criteria.[25](#ehf212209-bib-0025){ref-type="ref"} Hence, the diagnosis included the presence of non‐oedematous, non‐intentional weight loss of ≥5% over a period of at least 6 months.

Functional capacity assessment {#ehf212209-sec-0011}
------------------------------

The maximal muscle strength was assessed by handgrip strength measured by a handgrip dynamometer. The best of three measurements was used. The Short Physical Performance Battery (SPPB) test was performed according to standard protocol.[26](#ehf212209-bib-0026){ref-type="ref"} SPPB, a highly standardized geriatric test, consists of tests for balance, gait, strength, and endurance and evaluates the ability to stand with both feet together side‐by‐side, semi‐tandem, and tandem positions, time to walk 4 m, and time to rise from a chair and return to the seated position 5 times. SPPB scores range from 0 to 12 points, and lower SPPB scores indicate impaired mobility. In addition, all patients underwent treadmill cardiopulmonary exercise testing (spiroergometry) according to the modified Bruce protocol.[27](#ehf212209-bib-0027){ref-type="ref"} The modified Naughton protocol was used in selected patients.[28](#ehf212209-bib-0028){ref-type="ref"} A 6 min walk test was performed according to standard protocol[29](#ehf212209-bib-0029){ref-type="ref"} as previously described in the SICA‐HF study.[3](#ehf212209-bib-0003){ref-type="ref"}

Statistical analysis {#ehf212209-sec-0012}
--------------------

Data are presented as percentages, mean ± standard deviation. For all statistical analyses, IBM Statistical Package for the Social Sciences ([spss]{.smallcaps}) version 24.0 (IBM Co., Armonk, NY, USA) was used. Categorical data were analysed using Pearson\'s χ^2^ test or Fisher\'s exact test as appropriate, and parametric variables were analysed by Student\'s unpaired *t*‐test. Predictors of anorexia were evaluated by binary logistic regression analysis. To estimate the influence of anorexia on survival, Kaplan--Meier cumulative survival curves were constructed for illustrative purposes and compared by the Mantel--Haenzel log‐rank test. Moreover, the relationship of anorexia and cachexia with survival was assessed by Cox proportional hazard analysis (single predictor and multivariable analysis). Hazard ratio (HR) and 95% confidence interval (CI) for risk factors and significance level were used. A value of *P* \< 0.05 was considered to indicate statistical significance in all analyses.

Results {#ehf212209-sec-0013}
=======

Patient characteristics {#ehf212209-sec-0014}
-----------------------

Baseline characteristics of the study population are displayed in *Table* [1](#ehf212209-tbl-0001){ref-type="table-wrap"}. We enrolled 166 patients with clinically stable HF patients (25 female patients, 66 ± 12 years, LVEF 33.4 ± 9.9%, New York Heart Association class 2.3 ± 0.7, and 87.3% of whom presented with HF with reduced ejection fraction and the remaining with HF with preserved ejection fraction). Out of 166 total patients with HF, 57 patients (34%) reported any anorexia (*Figure* [1](#ehf212209-fig-0001){ref-type="fig"}). Patients with anorexia were those who had more advanced HF according to their functional class assessment (*P =* 0.008), higher impairment of their LVEF (*P =* 0.011), increased levels of high sensitive C‐reactive protein (*P =* 0.004) and serum creatinine (*P =* 0.009), were more likely to present with concomitant chronic kidney disease (*P =* 0.011) and cachexia (*P =* 0.013). However, no significant difference was found with regard to albumin level (37.0 ± 3.2 vs. 37.1 ± 4.2; *P =* 0.91) and NRI score (89.7 ± 9.0 vs. 92.4 ± 9.7; *P =* 0.64) in patients with vs. without anorexia. Moreover, body composition analysis also showed no significant differences in fat mass and fat‐free mass between the two groups. In addition, compared with patients without anorexia, anorexic patients were more likely to be on diuretic medication (75.5% vs. 96.5%, *P =* 0.001) and loop diuretics usage (56.9% vs. 78.9%, *P =* 0.006). The presence of muscle wasting without weight loss (sarcopenia) was not significantly different between anorexic and non‐anorexic patients. However, the patients suffering from both anorexia and cachexia showed higher prevalence of muscle wasting (patients with both anorexia and cachexia 40%, anorexia 13.9%, cachexia 10.0%, and neither anorexia nor cachexia 11.2%).

###### 

Clinical characteristics

                                               No anorexia (*n* = 109)   Anorexia (*n* = 57)  *P*‐value
  ------------------------------------------- ------------------------- --------------------- -----------
  Age (years)                                        65.8 ± 10.5             68.9 ± 10.3      0.067
  Female (*n*, %)                                       17.3                    14.0          0.663
  NYHA class I/II/III/IV (*n*)                       17/55/37/1               1/23/32/1       0.008
  BMI (kg/m^2^)                                      29.2 ± 5.0              27.8 ± 5.4       0.084
  Obesity (%)                                           38.2                    30.4          0.077
  Ischaemic HF (%)                                      60.0                    61.4          1.000
  LVEF (%)                                           34.8 ± 9.7              30.6 ± 10.1      0.011
  Co‐morbidity                                                                                
  Hypertention (%)                                      68.2                    63.2          0.293
  Hyperlipidaemia (%)                                   71.1                    67.3          0.701
  Diabetes (%)                                          40.0                    29.8          0.236
  CKD (%)                                               30.9                    52.6          0.011
  Anaemia (%)                                           27.3                    40.4          0.115
  Laboratory findings                                                                         
  High sensitive C‐reactive protein (mg/dL)           2.2 ± 1.6               3.1 ± 2.2       0.004
  Creatinin (mg/dL)                                   1.2 ± 0.4               1.4 ± 0.5       0.009
  Haemoglobin (g/dL)                                 13.5 ± 1.5              13.2 ± 1.7       0.362
  Albumin (mg/dL)                                    37.1 ± 4.2              37.0 ± 3.2       0.911
  Na (mEq/L)                                         141.1 ± 3.6             140.5 ± 4.6      0.384
  K (mEq/L)                                           4.5 ± 0.6               4.4 ± 0.6       0.683
  Cl (mEq/L)                                         103.0 ± 3.7             101.5 ± 4.3      0.024
  NRI (points)                                       92.4 ± 9.7              89.7 ± 9.0       0.635
  Medication                                                                                  
  ACE inhibitor (%)                                     68.8                    61.4          0.394
  ARB (%)                                               49.5                    54.4          0.625
  β‐blocker (%)                                         94.5                    91.2          0.546
  Digoxin (%)                                           10.1                    14.0          0.450
  Diuretics (%)                                         76.1                    96.5          0.001
  Loop diuretics (%)                                    56.9                    78.9          0.006
  Thiazides (%)                                         30.3                    31.6          0.861
  Aspirin (%)                                           74.3                    61.4          0.114
  Statin (%)                                            72.5                    68.4          0.721
  Amiodarone (%)                                        11.9                    15.8          0.478
  Functional capacity                                                                         
  Handgrip strength (kg)                             37.9 ± 12.0             35.8 ± 11.8      0.063
  SPPB (point)                                       10.8 ± 2.0              10.4 ± 1.6       0.047
  6 min walk test (m)                               439.0 ± 144.4           403.2 ± 162.9     0.010
  Peak VO~2~ (mL/min/kg)                             18.3 ± 5.1              15.2 ± 4.1       0.001
  Sarcopenia (%)                                        10.9                    21.1          0.064
  Cachexia (%)                                          18.2                    36.8          0.013

ACE, angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; BMI, Body mass index; Cl, chloride; CKD, Chronic kidney disease; K, potassium; LVEF, left ventricular ejection fraction; Na, sodium; NYHA, New York Heart Association; NRI, Nutritional Risk Index; peak VO~2~, peak oxygen uptake; SPPB, short physical performance battery; β‐blocker, beta‐adrenergic blocking agents.

![The prevalence of anorexia.](EHF2-4-448-g001){#ehf212209-fig-0001}

Association between anorexia and functional capacity {#ehf212209-sec-0015}
----------------------------------------------------

Functional capacity measurements are presented in *Table* [1](#ehf212209-tbl-0001){ref-type="table-wrap"}. Regarding physical performance and functional capacity, patients who reported anorexia showed lower SPPB score (10.4 ± 1.6 vs. 10.8 ± 2.0 points; *P =* 0.047), 6 min walk distance (403.2 ± 162.9 vs. 439.0 ± 144.4 m; *P =* 0.010), and peak VO~2~ (15.2 ± 4.1 vs. 18.3 ± 5.1 mL/min/kg; *P =* 0.001).

Finally, we investigated the effects of cachexia among patients with or without anorexia. *Figure* [2](#ehf212209-fig-0002){ref-type="fig"} demonstrates the association between functional capacity and the presence of anorexia in the respective groups. The SPPB score, 6 min walk distance, and peak VO~2~ showed worse results among patients suffering from both anorexia and cachexia.

![Impact of anorexia and cachexia on functional capacity in patients with heart failure. †*P* \< 0.05 vs. no anorexia, ‡*P* \< 0.05 vs. anorexia without cachexia. Peak VO~2~, peak oxygen consumption; SPPB, short physical performance battery.](EHF2-4-448-g002){#ehf212209-fig-0002}

Determinants of anorexia in patients with heart failure {#ehf212209-sec-0016}
-------------------------------------------------------

Using logistic regression analysis with the presence of anorexia serving as the dependent variable, we found that NYHA class, LVEF, presence of chronic kidney disease, high sensitive C‐reactive protein, cachexia, and loop diuretics usage predicted the presence of anorexia in patients with HF (*Table* [2](#ehf212209-tbl-0002){ref-type="table-wrap"}). Multivariate regression analysis showed that high sensitive C‐reactive protein \[odds ratio (OR) 1.24, *P =* 0.04\], loop diuretic use (OR 5.76, *P =* 0.03), and cachexia (OR 2.53, *P =* 0.04) remained independent predictors of anorexia in patients with HF (*Table* [2](#ehf212209-tbl-0002){ref-type="table-wrap"}).

###### 

Logistic regression model with anorexia serving as the dependent variable

                                                          Univariate   Multivariate                                   
  ------------------------------------------------------- ------------ -------------- --------------- ------- ------- ---------------
  NYHA class \[1 class increase\]                         2.442        0.001          1.435--4.155    1.660   0.133   0.858--3.212
  LVEF \[1% increase\]                                    0.955        0.013          0.920--0.990    0.997   0.905   0.956--1.041
  CKD \[presence\]                                        2.418        0.009          1.250--4.678    1.803   0.172   0.774--4.201
  High sensitive C‐reactive protein \[1 μg/L increase\]   1.275        0.012          1.056--1.539    1.240   0.043   1.007--1.527
  Cachexia \[presence\]                                   2.596        0.010          1.258--5.357    2.532   0.042   1.036--6.190
  Loop diuretics \[use\]                                  8.614        0.004          1.965--37.769   5.759   0.028   1.207--27.466

CI, confidence interval; CKD, chronic kidney disease; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.

Impact of anorexia on cumulative survival rate in patients with heart failure {#ehf212209-sec-0017}
-----------------------------------------------------------------------------

In the total population, 2‐year all‐cause mortality was 22 (13.3%) among clinically stable ambulatory HF patients. Our findings showed that all‐cause mortality was significantly higher in patients with any anorexia. The all‐cause mortality rate was 22.8% after a mean follow‐up of 22.5 ± 5.1 months (95% CI 2.336--6.634) in patients with anorexia when compared with 8.2% (95% CI 4.532--19.690) in patients without anorexia (*P =* 0.014). Kaplan--Meier curves for cumulative survival showed that those patients with anorexia presented higher mortality rate within 24 months (Log‐rank test *P =* 0.029, *Figure* [3](#ehf212209-fig-0003){ref-type="fig"}) than those without. Similarly, the all‐cause mortality rate was 24.4% (95% CI 0.08--0.20) in patients with cachexia when compared with 9.6% (95% CI 0.11--0.38) in patients without cachexia (*P =* 0.03). Using univariate Cox analysis, it was shown that anorexia is associated with 2‐year all‐cause mortality (HR 2.466, 95% CI 1.065--5.709, *P =* 0.035). In multivariate Cox analysis, anorexia was not a significant independent predictor of 2‐year all‐cause mortality (adjusted HR 2.124, 95% CI 0.903--4.995, *P =* 0.054) after adjusting for potential confounders such as age, gender, LVEF, and NYHA class, unlike cachexia (adjusted HR 2.395, 95% CI 1.018--5.631, *P =* 0.045). We investigated the effects of cachexia among patients with or without anorexia. Multivariate Cox analysis showed that cachexia has additive effect on increasing mortality among HF patients with anorexia. Anorexic patients with cachexia showed increased mortality rates (adjusted HR: 2.856, 95% CI 1.032--7.902, *P =* 0.043) after adjusting for potential confounders such as age, gender, LVEF, and NYHA class (*Table* [3](#ehf212209-tbl-0003){ref-type="table-wrap"}).

![Kaplan--Meier survival curve.](EHF2-4-448-g003){#ehf212209-fig-0003}

###### 

Mortality risk according to the presence of anorexia and cachexia in heart failure patients

                              Crude model     Adjusted model[a](#ehf212209-note-0003){ref-type="fn"}                                          
  --------------------------- --------------- -------------------------------------------------------- ------- --------------- -------------- -------
  No anorexia                 1 (reference)                                                                    1 (reference)                  
  Anorexia without cachexia   1.903           0.492--7.360                                             0.351   1.986           0.501--7.872   0.329
  Anorexia with cachexia      5.018           1.758--14.320                                            0.003   2.993           0.995--9.000   0.051

CI, confidence interval; HR, hazard ratio.

Adjusted model: adjusted for age, gender, left ventricular ejection fraction, and New York Heart Association class.

Discussion {#ehf212209-sec-0018}
==========

In the present study, more than one‐third of clinically stable ambulatory patients with HF reported any anorexia. Using multivariable regression analysis, we identified an increased level of inflammation, loop diuretic use, and the presence of cachexia as major determinants of anorexia in patients with HF. Our findings demonstrate that patients with anorexia are more likely to present with impaired functional capacity and higher all‐cause mortality within 2 years. Moreover, cachexia showed additive effects of worsening functional capacity and poor outcomes in patients with HF and anorexia. Previous studies have shown that anorexia is not an unavoidable consequence of chronic disease, and it often promotes its development through various mechanisms.[30](#ehf212209-bib-0030){ref-type="ref"}

In the present study, cachexia was more frequently detected in patients with anorexia (36.8%) compared with those without (18.2%), and cachexia remained an independent predictor of anorexia in our cohort. The complex clinical nature of HF‐induced anorexia or HF‐induced cachexia suggested a multifactorial aetiology. In addition to cachexia, inflammation, medication side effects, depression, anxiety, sodium restricted diets, and chewing problem may also be found as cause of anorexia.[31](#ehf212209-bib-0031){ref-type="ref"} Some patients therefore appear anorexia symptom before sign and symptoms of cachexia even though patients were not severe HF patients. In these cases, it may be suspected that anorexia inevitably leads to cachexia. On the other hand, some patients have cachexia despite maintaining a relatively normal appetite and nutritional intake.[32](#ehf212209-bib-0032){ref-type="ref"} Therefore, elucidating the underlying mechanism for anorexia--cachexia syndrome was challenging in patients with HF. Currently, the anorexia--cachexia syndrome has been recognized as an adverse consequence of disease, and its treatment remains a clinical challenge in oncology patients.[33](#ehf212209-bib-0033){ref-type="ref"} Anorexia--cachexia syndrome is often associated with the underlying disease process and related to both peripheral and central neurohormonal signals regulating both appetite and energy expenditure. Moreover, cachexia was related to intestinal congestion and can further worsen anorexia and impaired food intake in patients with HF.[15](#ehf212209-bib-0015){ref-type="ref"}, [34](#ehf212209-bib-0034){ref-type="ref"} An increase in circulating inflammatory cytokines including C‐reactive protein, which is the most frequently measured inflammatory marker is one of the pathogenic mechanism of anorexia and food intake in chronic disease.[35](#ehf212209-bib-0035){ref-type="ref"} One of the targets of inflammatory mediators is the central nervous system, particularly on regulatory feeding centers in the hypothalamus sited in the ventral diencephalon. Recently, several studies explained the mechanisms by which inflammation reaches the hypothalamus and the neural substrates underlying inflammatory anorexia.[36](#ehf212209-bib-0036){ref-type="ref"} Furthermore, pro‐inflammatory cytokines persistently activate pro‐opiomelanocortin neurons and inhibit neuropeptide Y neurons, and both are involved in the alteration of satiety and hunger signals (the clinical signs of anorexia and cachexia).[37](#ehf212209-bib-0037){ref-type="ref"}

Conventional HF treatment includes angiotensin‐converting enzyme inhibitors and beta‐blockers and reduces the risk of weight loss.[38](#ehf212209-bib-0038){ref-type="ref"}, [39](#ehf212209-bib-0039){ref-type="ref"} In this context, one of the most important issues for managing anorexia is to maintain optimal HF treatment. Moreover, energy‐protein nutritional supplement and essential amino acids were efficacious in body weight, muscle metabolism, and inflammatory system in patients with HF.[40](#ehf212209-bib-0040){ref-type="ref"}, [41](#ehf212209-bib-0041){ref-type="ref"} Recently, several agents such as ghrelin, megestrol acetate, medroxyprogesterone acetate, and synthetic cannabinoids are used clinically to stimulate appetite in patients with disease‐related wasting; however, these agents are very limited in patients with HF.[42](#ehf212209-bib-0042){ref-type="ref"} However, another possible cause of anorexia could be a side effect of treatment of HF or HF‐induced wasting.[43](#ehf212209-bib-0043){ref-type="ref"} Several HF treatments could contribute to inadequate food intake, especially overzealous diuretic use, which can cause anorexia in animal experiments.[44](#ehf212209-bib-0044){ref-type="ref"} For instance, the use of loop diuretics is associated with up‐regulation of the activity of the renin--angiotensin--aldosterone system,[45](#ehf212209-bib-0045){ref-type="ref"}, [46](#ehf212209-bib-0046){ref-type="ref"} and higher doses of diuretics are associated with poor outcomes in patients with HF.[47](#ehf212209-bib-0047){ref-type="ref"} Angiotensin II, the primary contributor of renin--angiotensin--aldosterone system, causes anorexia and reduces food intake in rodents.[48](#ehf212209-bib-0048){ref-type="ref"} Long‐term use of diuretics in HF is also linked to the deficiency of micronutrients such as zinc.[30](#ehf212209-bib-0030){ref-type="ref"}, [49](#ehf212209-bib-0049){ref-type="ref"} Diuretics could stimulate the urinary excretion of zinc decreasing perception of taste, anorexia, and inadequate food intake.[50](#ehf212209-bib-0050){ref-type="ref"} In addition, appetite stimulants, megestrol acetate and medroxyprogesterone acetate, were generally not recommended for patients with HF, because these appetite stimulants increase in weight gain and peripheral oedema caused by fluid retention.[51](#ehf212209-bib-0051){ref-type="ref"} Similarly, synthetic cannabinoids have adverse side effects such as postural hypotension owing to reduced vascular resistance. For this reason, it is recommended to avoid usage of these appetite stimulants in patients with HF.

Several studies conducted in elderly patients with cancer and other chronic diseases showed that anorexia was associated with impaired muscle mass, functional capacity, increased risk of frailty, disability, and impaired quality of life.[13](#ehf212209-bib-0013){ref-type="ref"}, [52](#ehf212209-bib-0052){ref-type="ref"}, [53](#ehf212209-bib-0053){ref-type="ref"} Landi and collaborators showed significantly lower SPPB score in anorexic patients compared with those without (−1.0 point, *P =* 0.03).[52](#ehf212209-bib-0052){ref-type="ref"} Moreover, they clearly showed that these patients have remarkable decline in functional capacity and activities of daily living. Comparably, our findings also show declined functional capacity including SPPB score, distance of 6 min walk test, and peak VO~2~ in patients with HF and anorexia. The frequency of anorexia symptoms is associated with the presence of sarcopenia in our patients. In addition, cachexia showed an additive effect in worsening functional capacity in patients with HF and anorexia. Therefore, it is crucial to detect the presence of anorexia and cachexia to reduce co‐morbidities and to preserve functional capacity in patients with HF.

Another important finding of our study is the association between anorexia and increased mortality. Older nursing home residents with anorexia had a higher risk of death for all‐causes compared with non‐anorexic participants (HR 2.26, 95% CI 2.14--2.38).[54](#ehf212209-bib-0054){ref-type="ref"} In chronic renal failure, mortality risk in anorexic patients was 4 to 5 times that of those without anorexia.[55](#ehf212209-bib-0055){ref-type="ref"} Thus, several studies mentioned that anorexia is one of the predictors of mortality in elderly subjects and in patients with chronic disease.[35](#ehf212209-bib-0035){ref-type="ref"}, [56](#ehf212209-bib-0056){ref-type="ref"} However, there are few reports pointing out the association between anorexia and clinical outcome in patients with HF. In the unadjusted model of our findings, we observed that anorexia potentially correlated with poor clinical outcome in patients with HF. Moreover, patients with anorexia and cachexia were strongly associated with mortality risk after adjusting for potential confounders. Our findings have an important clinical implication, because our results may help to better understand the relationship between anorexia, cachexia and impaired functional capacity and poor outcomes in patients with HF.

There are limitations associated with our study. In order to diagnose anorexia, it is important to have valid and reliable instruments. Recently, two instruments with high face validity were recommended to diagnose anorexia in patients with cancer anorexia--cachexia syndrome.[53](#ehf212209-bib-0053){ref-type="ref"} The first instrument is a yes/no question 'Did you have a decrease appetite during the last month?'. The second instrument is anorexia symptom scale, which consists of one item of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire‐C30.[57](#ehf212209-bib-0057){ref-type="ref"} On the other hand, there is no standard instrument to diagnose anorexia in patients with HF. Moreover, we did not collect the information of dietary intake, and therefore, we do not know whether the patients with anorexia have deficiency of energy or protein intake. Future research should focus on the definitions and instruments of anorexia and dietary intake in patients with HF.

Conclusions {#ehf212209-sec-0019}
===========

The present study shows that inflammation, loop diuretic use, and cachexia are independent predictors of anorexia in patients with HF. Moreover, anorexia is associated with impaired functional capacity and increased mortality risk. Nutritional habits and status are frequently disregarded, and its evaluation should be included as a fundamental part in the overall assessment of ambulatory patients with HF.
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